Whalen Wealth Management Inc. Buys Shares of 4,620 Ascendis Pharma A/S $ASND

Whalen Wealth Management Inc. purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the third quarter, Holdings Channel.com reports. The fund purchased 4,620 shares of the biotechnology company’s stock, valued at approximately $919,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Perceptive Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the second quarter valued at approximately $166,367,000. Adage Capital Partners GP L.L.C. bought a new position in Ascendis Pharma A/S during the 1st quarter valued at $51,029,000. RA Capital Management L.P. boosted its stake in Ascendis Pharma A/S by 1.7% during the 1st quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock valued at $1,602,474,000 after purchasing an additional 168,752 shares in the last quarter. Braidwell LP acquired a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $16,632,000. Finally, Marshall Wace LLP raised its stake in shares of Ascendis Pharma A/S by 425.5% in the 2nd quarter. Marshall Wace LLP now owns 117,162 shares of the biotechnology company’s stock worth $20,222,000 after buying an additional 94,868 shares in the last quarter.

Wall Street Analysts Forecast Growth

ASND has been the subject of several research reports. JPMorgan Chase & Co. raised their target price on Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Wedbush reissued an “outperform” rating and issued a $220.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, November 18th. Wolfe Research began coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, November 18th. They issued a “peer perform” rating and a $255.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Finally, Raymond James Financial assumed coverage on shares of Ascendis Pharma A/S in a report on Friday, October 17th. They set a “strong-buy” rating and a $271.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $256.73.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $199.80 on Friday. The company has a 50-day moving average of $205.99 and a two-hundred day moving average of $192.41. The stock has a market cap of $12.37 billion, a price-to-earnings ratio of -45.00 and a beta of 0.45. Ascendis Pharma A/S has a one year low of $118.03 and a one year high of $229.94.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $250.71 million for the quarter, compared to analyst estimates of $246.91 million. Analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.